CMR characteristics of TTS and controls, the imaging test was performed at a median of 4 days after admission
| Variable . | TTS (n = 32) . | Controls (n = 23) . | P . |
|---|---|---|---|
| Symptom onset to CMR (days) | 4 (3, 7) | — | — |
| Admission to CMR (days) | 4 (2, 6) | — | — |
| Cardiac volumes and function | |||
| LVEDV index (mL/m2) | 76 ± 18 | 74 ± 13 | 0.645 |
| LVESV index (mL/m2) | 39 ± 15 | 29 ± 8 | 0.008 |
| LVEF (%) | 49 ± 12 | 61 ± 5 | <0.001 |
| LV mass index (g/m2) | 55 ± 11 | 46 ± 8 | <0.001 |
| RVEDV index (mL/m2) | 62 ± 14 | 72 ± 14 | 0.007 |
| RVESV index (mL/m2) | 28 ± 8 | 31 ± 10 | 0.193 |
| RVEF (%) | 55 ± 8 | 58 ± 7 | 0.114 |
| Myocardial deformation | |||
| LV GLS (%) | 17 ± 4 | 24 ± 4 | <0.001 |
| LV basal CS (%) | 23 ± 3 | 24 ± 4 | 0.351 |
| LV mid CS (%) | 15 ± 5 | 19 ± 3 | <0.001 |
| LV apical CS (%) | 15 ± 7 | 22 ± 4 | <0.001 |
| LV GCS (%) | 16 ± 4 | 22 ± 3 | <0.001 |
| Tissue mapping | |||
| Septal native T1 (msec) | 1116 ± 73 | 970 ± 23 | <0.001 |
| Basal native T1 (msec) | 1044 ± 38 | 989 ± 22 | <0.001 |
| Mid native T1 (msec) | 1118 ± 66 | 983 ± 27 | <0.001 |
| Apical native T1 (msec) | 1136 ± 95 | 995 ± 36 | <0.001 |
| Global native T1 (msec) | 1094 ± 51 | 988 ± 23 | <0.001 |
| Septal T2 (msec) | 56 ± 5 | 46 ± 2 | <0.001 |
| Basal T2 (msec) | 51 ± 4 | 48 ± 2 | 0.004 |
| Mid T2 (msec) | 58 ± 5 | 48 ± 2 | <0.001 |
| Apical T2 (msec) | 62 ± 6 | 49 ± 3 | <0.001 |
| Global T2 (msec) | 56 ± 4 | 48 ± 2 | <0.001 |
| T2 apicobasal gradient (msec) | 12 ± 6 | 2 ± 2 | <0.001 |
| Septal ECV (%) | 32 ± 5 | 24 ± 1 | <0.001 |
| Basal ECV (%) | 30 ± 3 | 25 ± 2 | <0.001 |
| Mid ECV (%) | 31 ± 5 | 25 ± 2 | <0.001 |
| Apical ECV (%) | 34 ± 6 | 27 ± 2 | <0.001 |
| Global ECV (%) | 31 ± 4 | 25 ± 2 | <0.001 |
| Variable . | TTS (n = 32) . | Controls (n = 23) . | P . |
|---|---|---|---|
| Symptom onset to CMR (days) | 4 (3, 7) | — | — |
| Admission to CMR (days) | 4 (2, 6) | — | — |
| Cardiac volumes and function | |||
| LVEDV index (mL/m2) | 76 ± 18 | 74 ± 13 | 0.645 |
| LVESV index (mL/m2) | 39 ± 15 | 29 ± 8 | 0.008 |
| LVEF (%) | 49 ± 12 | 61 ± 5 | <0.001 |
| LV mass index (g/m2) | 55 ± 11 | 46 ± 8 | <0.001 |
| RVEDV index (mL/m2) | 62 ± 14 | 72 ± 14 | 0.007 |
| RVESV index (mL/m2) | 28 ± 8 | 31 ± 10 | 0.193 |
| RVEF (%) | 55 ± 8 | 58 ± 7 | 0.114 |
| Myocardial deformation | |||
| LV GLS (%) | 17 ± 4 | 24 ± 4 | <0.001 |
| LV basal CS (%) | 23 ± 3 | 24 ± 4 | 0.351 |
| LV mid CS (%) | 15 ± 5 | 19 ± 3 | <0.001 |
| LV apical CS (%) | 15 ± 7 | 22 ± 4 | <0.001 |
| LV GCS (%) | 16 ± 4 | 22 ± 3 | <0.001 |
| Tissue mapping | |||
| Septal native T1 (msec) | 1116 ± 73 | 970 ± 23 | <0.001 |
| Basal native T1 (msec) | 1044 ± 38 | 989 ± 22 | <0.001 |
| Mid native T1 (msec) | 1118 ± 66 | 983 ± 27 | <0.001 |
| Apical native T1 (msec) | 1136 ± 95 | 995 ± 36 | <0.001 |
| Global native T1 (msec) | 1094 ± 51 | 988 ± 23 | <0.001 |
| Septal T2 (msec) | 56 ± 5 | 46 ± 2 | <0.001 |
| Basal T2 (msec) | 51 ± 4 | 48 ± 2 | 0.004 |
| Mid T2 (msec) | 58 ± 5 | 48 ± 2 | <0.001 |
| Apical T2 (msec) | 62 ± 6 | 49 ± 3 | <0.001 |
| Global T2 (msec) | 56 ± 4 | 48 ± 2 | <0.001 |
| T2 apicobasal gradient (msec) | 12 ± 6 | 2 ± 2 | <0.001 |
| Septal ECV (%) | 32 ± 5 | 24 ± 1 | <0.001 |
| Basal ECV (%) | 30 ± 3 | 25 ± 2 | <0.001 |
| Mid ECV (%) | 31 ± 5 | 25 ± 2 | <0.001 |
| Apical ECV (%) | 34 ± 6 | 27 ± 2 | <0.001 |
| Global ECV (%) | 31 ± 4 | 25 ± 2 | <0.001 |
Takotsubo syndrome (TTS), Left ventricle (LV), LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), LV ejection fraction (LVEF), right ventricle (RV), RV end-diastolic volume (RVEDV), RV end-systolic volume (RVESV), RV ejection fraction (RVEF), global longitudinal strain (GLS), circumferential strain (CS), global circumferential strain (GCS), extracellular volume (ECV).
CMR characteristics of TTS and controls, the imaging test was performed at a median of 4 days after admission
| Variable . | TTS (n = 32) . | Controls (n = 23) . | P . |
|---|---|---|---|
| Symptom onset to CMR (days) | 4 (3, 7) | — | — |
| Admission to CMR (days) | 4 (2, 6) | — | — |
| Cardiac volumes and function | |||
| LVEDV index (mL/m2) | 76 ± 18 | 74 ± 13 | 0.645 |
| LVESV index (mL/m2) | 39 ± 15 | 29 ± 8 | 0.008 |
| LVEF (%) | 49 ± 12 | 61 ± 5 | <0.001 |
| LV mass index (g/m2) | 55 ± 11 | 46 ± 8 | <0.001 |
| RVEDV index (mL/m2) | 62 ± 14 | 72 ± 14 | 0.007 |
| RVESV index (mL/m2) | 28 ± 8 | 31 ± 10 | 0.193 |
| RVEF (%) | 55 ± 8 | 58 ± 7 | 0.114 |
| Myocardial deformation | |||
| LV GLS (%) | 17 ± 4 | 24 ± 4 | <0.001 |
| LV basal CS (%) | 23 ± 3 | 24 ± 4 | 0.351 |
| LV mid CS (%) | 15 ± 5 | 19 ± 3 | <0.001 |
| LV apical CS (%) | 15 ± 7 | 22 ± 4 | <0.001 |
| LV GCS (%) | 16 ± 4 | 22 ± 3 | <0.001 |
| Tissue mapping | |||
| Septal native T1 (msec) | 1116 ± 73 | 970 ± 23 | <0.001 |
| Basal native T1 (msec) | 1044 ± 38 | 989 ± 22 | <0.001 |
| Mid native T1 (msec) | 1118 ± 66 | 983 ± 27 | <0.001 |
| Apical native T1 (msec) | 1136 ± 95 | 995 ± 36 | <0.001 |
| Global native T1 (msec) | 1094 ± 51 | 988 ± 23 | <0.001 |
| Septal T2 (msec) | 56 ± 5 | 46 ± 2 | <0.001 |
| Basal T2 (msec) | 51 ± 4 | 48 ± 2 | 0.004 |
| Mid T2 (msec) | 58 ± 5 | 48 ± 2 | <0.001 |
| Apical T2 (msec) | 62 ± 6 | 49 ± 3 | <0.001 |
| Global T2 (msec) | 56 ± 4 | 48 ± 2 | <0.001 |
| T2 apicobasal gradient (msec) | 12 ± 6 | 2 ± 2 | <0.001 |
| Septal ECV (%) | 32 ± 5 | 24 ± 1 | <0.001 |
| Basal ECV (%) | 30 ± 3 | 25 ± 2 | <0.001 |
| Mid ECV (%) | 31 ± 5 | 25 ± 2 | <0.001 |
| Apical ECV (%) | 34 ± 6 | 27 ± 2 | <0.001 |
| Global ECV (%) | 31 ± 4 | 25 ± 2 | <0.001 |
| Variable . | TTS (n = 32) . | Controls (n = 23) . | P . |
|---|---|---|---|
| Symptom onset to CMR (days) | 4 (3, 7) | — | — |
| Admission to CMR (days) | 4 (2, 6) | — | — |
| Cardiac volumes and function | |||
| LVEDV index (mL/m2) | 76 ± 18 | 74 ± 13 | 0.645 |
| LVESV index (mL/m2) | 39 ± 15 | 29 ± 8 | 0.008 |
| LVEF (%) | 49 ± 12 | 61 ± 5 | <0.001 |
| LV mass index (g/m2) | 55 ± 11 | 46 ± 8 | <0.001 |
| RVEDV index (mL/m2) | 62 ± 14 | 72 ± 14 | 0.007 |
| RVESV index (mL/m2) | 28 ± 8 | 31 ± 10 | 0.193 |
| RVEF (%) | 55 ± 8 | 58 ± 7 | 0.114 |
| Myocardial deformation | |||
| LV GLS (%) | 17 ± 4 | 24 ± 4 | <0.001 |
| LV basal CS (%) | 23 ± 3 | 24 ± 4 | 0.351 |
| LV mid CS (%) | 15 ± 5 | 19 ± 3 | <0.001 |
| LV apical CS (%) | 15 ± 7 | 22 ± 4 | <0.001 |
| LV GCS (%) | 16 ± 4 | 22 ± 3 | <0.001 |
| Tissue mapping | |||
| Septal native T1 (msec) | 1116 ± 73 | 970 ± 23 | <0.001 |
| Basal native T1 (msec) | 1044 ± 38 | 989 ± 22 | <0.001 |
| Mid native T1 (msec) | 1118 ± 66 | 983 ± 27 | <0.001 |
| Apical native T1 (msec) | 1136 ± 95 | 995 ± 36 | <0.001 |
| Global native T1 (msec) | 1094 ± 51 | 988 ± 23 | <0.001 |
| Septal T2 (msec) | 56 ± 5 | 46 ± 2 | <0.001 |
| Basal T2 (msec) | 51 ± 4 | 48 ± 2 | 0.004 |
| Mid T2 (msec) | 58 ± 5 | 48 ± 2 | <0.001 |
| Apical T2 (msec) | 62 ± 6 | 49 ± 3 | <0.001 |
| Global T2 (msec) | 56 ± 4 | 48 ± 2 | <0.001 |
| T2 apicobasal gradient (msec) | 12 ± 6 | 2 ± 2 | <0.001 |
| Septal ECV (%) | 32 ± 5 | 24 ± 1 | <0.001 |
| Basal ECV (%) | 30 ± 3 | 25 ± 2 | <0.001 |
| Mid ECV (%) | 31 ± 5 | 25 ± 2 | <0.001 |
| Apical ECV (%) | 34 ± 6 | 27 ± 2 | <0.001 |
| Global ECV (%) | 31 ± 4 | 25 ± 2 | <0.001 |
Takotsubo syndrome (TTS), Left ventricle (LV), LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), LV ejection fraction (LVEF), right ventricle (RV), RV end-diastolic volume (RVEDV), RV end-systolic volume (RVESV), RV ejection fraction (RVEF), global longitudinal strain (GLS), circumferential strain (CS), global circumferential strain (GCS), extracellular volume (ECV).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
